Virus News and Research

Latest Virus News and Research

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Discovery Laboratories, Inc., reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute Respiratory Failure (ARF), a critical condition often caused in children by severe respiratory infections. The objective of the study was to evaluate the safety and tolerability of intratracheal administration of Surfaxin and to assess whether Surfaxin treatment could decrease the duration of mechanical ventilation in children with ARF.

9 Jun 2010

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

An inexpensive system for earlier disease diagnosis could save innumerable lives. It would also have a profound impact on the nation's healthcare industry, currently buckling under the strain of spiraling costs.

9 Jun 2010

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

NanoViricides, Inc. reports that its anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.

8 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

New technique to prevent tumours developing in connection with stem cell transplantations

Researchers at Lund University have come up with a new technique to prevent tumours developing in connection with stem cell transplantations. The results have been published today in the respected scientific journal PNAS.

8 Jun 2010

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Adding another feat to the history of cardiothoracic surgery at Fortis Hospitals Bangalore, the team of experts led by noted Dr. Vivek Jawali, Chief Cardiothoracic Surgeon and Dr. Ramcharan Thiagarajan, Consultant Surgical GI & Hepato-Pancreatic Biliary Surgoen has performed a combined cardiac bypass and liver tumor surgery on a 63 year old Nigerian.

8 Jun 2010

Researchers decipher how mast cells set immune defense on right track

In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.

8 Jun 2010

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

Researchers from the BC Centre for Excellence in HIV/AIDS and the University of British Columbia today released a comprehensive study revealing that the 2008 IAS-USA therapy guidelines for commencing HIV treatment would create significant benefits for individuals infected with HIV and society as a whole.

8 Jun 2010

$Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010$

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.

8 Jun 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

7 Jun 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics, Inc. today announced positive results from a Phase 2 clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. The trial met the primary endpoint of efficacy, as measured by objective response rate or lack of early disease progression. Overall response rate was 23.1%, in evaluable patients, and median progression-free survival was 4.3 months. The results were presented at the American Society of Clinical Oncology meeting.

7 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Researchers discover svRNA component that may help develop universal anti-viral treatment

Researchers at Mount Sinai School of Medicine have discovered a novel component of the influenza virus that may be the key to disabling the virus's ability to replicate itself and to developing a universal anti-viral treatment. The findings were published June 1 online in Proceedings of the National Academy of Sciences.

4 Jun 2010

WHO says H1N1 remains pandemic

WHO Director-General Margaret Chan on Thursday announced the WHO still considers H1N1 (swine) flu a pandemic, despite the fact "its most intense activity has passed in many parts of the world," Reuters reports (Lynn, 6/3).

4 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

MedImmune today announced that the U.S. Food and Drug Administration's Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus disease in high-risk infants.

3 Jun 2010

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

The National Institutes of Health has awarded scientists at Albert Einstein College of Medicine of Yeshiva University a five-year, $3.9 million grant to study how extensively drug-resistant tuberculosis is transmitted in rural South Africa. The findings could alter public health approaches for controlling the XDR-TB epidemic in the developing world.

3 Jun 2010

Universal testing for HIV can do more harm than good

The idea of early detection and cure is appealing. But if the test is unreliable, and the treatment itself harmful, universal testing can do more harm than good.

3 Jun 2010

Virus News and Research

Latest Virus News and Research

Discovery Labs reports preliminary results from Surfaxin Phase 2 trial in children with Acute Respiratory Failure

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

NanoViricides anti-HIV drug candidates demonstrate efficacy in cell culture studies with HIV-1 isolates

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

New technique to prevent tumours developing in connection with stem cell transplantations

Combined cardiac bypass and liver tumor surgery performed on 63-year-old Nigerian

Researchers decipher how mast cells set immune defense on right track

Updated HIV treatment guidelines may benefit individuals infected with HIV: Researchers

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Researchers discover svRNA component that may help develop universal anti-viral treatment

WHO says H1N1 remains pandemic

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

Case report on clear cell ICC

Motavizumab should not be licensed for marketing: FDA Antiviral Drugs Advisory Committee

Scientists awarded $3.9M grant to study how XDR-TB transmitted in rural South Africa

Universal testing for HIV can do more harm than good

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in